IDEXX Laboratories, Inc. (IDXX) Stock Analysis
Temp Headwind edge
Healthcare · Diagnostics & Research
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $561.38 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole or single sources, such as Ortho; Earnings in 5 days (event risk).
IDEXX Laboratories develops, manufactures, and distributes diagnostic products and software for the companion animal veterinary, livestock/poultry/dairy, and water testing markets globally. Revenue comes from recurring instrument consumable sales, reference laboratory services,... Read more
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $561.38 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole or single sources, such as Ortho; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole or single sources, such as Ortho10-K Item 1A: 'we currently purchase many products, components, and materials from sole or single sources, such as Ortho.'
Material Events(8-K, last 90d)
- 2026-03-26Item 5.02MEDIUMIDEXX and Nimrata Hunt, PhD (EVP Global Strategy and Commercial) mutually agreed she will cease in her current role April 13, 2026, continuing advisory services until July 13, 2026. Separation agreement executed with salary and bonus continuation. No successor named.SEC filing →
- 2026-02-13Item 5.02LOWDirector M. Anne Szostak notified IDEXX of intention to retire from the Board effective following the 2026 Annual Meeting on May 12, 2026. Decision does not arise from any disagreement. Board size to be reduced upon her retirement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $561.38 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole or single sources, such as Ortho; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $527.69. Score 5.1/10, moderate confidence.
Take-profit target: $630.31 (+12.4% upside). Prior stop was $527.69. Stop-loss: $527.69.
Concentration risk — Supplier: sole or single sources, such as Ortho; Earnings in 5 days (event risk); Expensive valuation.
IDEXX Laboratories, Inc. trades at a P/E of 42.4 (forward 33.8). TrendMatrix value score: 3.3/10. Verdict: Sell.
22 analysts cover IDXX with a consensus score of 4.0/5. Average price target: $725.
What does IDEXX Laboratories, Inc. do?IDEXX Laboratories develops, manufactures, and distributes diagnostic products and software for the companion animal...
IDEXX Laboratories develops, manufactures, and distributes diagnostic products and software for the companion animal veterinary, livestock/poultry/dairy, and water testing markets globally. Revenue comes from recurring instrument consumable sales, reference laboratory services, and software subscriptions to veterinarians, research institutions, and government labs.